The acquired company is developing Lim Transseptal System to fulfil the demands of left-sided structural heart procedures that require a transseptal approach.
The system is expected to play a vital role in procedures such as percutaneous treatment of mitral valve disease, percutaneous occlusion of the left atrial appendage and electrophysiology procedures.
It is said to make transseptal punctures more effective and efficient while reducing costly complications and offering a greater level of device control, functionality and visibility.
Lim Transseptal System is expected to expand Keystone Heart’s portfolio of total package solutions for structural heart procedures.
The device is currently not cleared for use or commercial distribution in the US and is not CE marked.
510 Kardiac Devices co-founder and CEO Jaime Sarabia said: “We are excited to be joining an innovative company like Keystone Heart.
“Procedures requiring a transseptal approach will grow dramatically over the next several years, and the Lim Transseptal System will help to differentiate Keystone Heart as a leader within these new therapies. This partnership provides us with the distinct opportunity to bring our pioneering technology into the US and Europe by partnering with a team that is known for excellent product development and go-to market experience.”
Keystone Heart president and CEO Chris Richardson said: “At Keystone Heart, we are dedicated to delivering innovative products that fulfil unmet needs like our TriGUARD 3, which is the only CE-marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures.
“Adding the Lim Transseptal System allows us to broaden our portfolio and fortify our long-term strategy of offering total package solutions for structural heart procedures.”